2010. Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia. Mediterranean Journal of Hematology and Infectious Diseases. 2, 2 (May 2010), e2010012. DOI:https://doi.org/10.4084/mjhid.2010.012.